United Bank Invests $1.28 Million in CVS Health Corporation $CVS

United Bank purchased a new stake in CVS Health Corporation (NYSE:CVS) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 17,879 shares of the pharmacy operator’s stock, valued at approximately $1,284,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Hamlin Capital Management LLC purchased a new stake in CVS Health during the fourth quarter worth $160,844,000. Capitolis Liquid Global Markets LLC acquired a new stake in CVS Health in the third quarter valued at $11,308,000. National Bank of Canada FI increased its position in shares of CVS Health by 50.3% in the third quarter. National Bank of Canada FI now owns 1,770,840 shares of the pharmacy operator’s stock valued at $133,495,000 after buying an additional 593,015 shares in the last quarter. State Street Corp raised its stake in shares of CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock worth $4,776,182,000 after buying an additional 1,245,457 shares during the last quarter. Finally, Fort Washington Investment Advisors Inc. OH boosted its position in shares of CVS Health by 2.9% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 725,189 shares of the pharmacy operator’s stock worth $57,551,000 after buying an additional 20,217 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CVS shares. Piper Sandler reissued an “overweight” rating and issued a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. Cantor Fitzgerald upped their price target on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. HSBC reiterated a “hold” rating and issued a $103.00 price target on shares of CVS Health in a research report on Monday, July 6th. Sanford C. Bernstein lifted their price objective on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 12th. Finally, Morgan Stanley upped their target price on CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Twenty-one investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $102.84.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health declared a quarterly dividend of $0.665 per share, reinforcing its shareholder-return policy and signaling management confidence in cash generation. CVS Health declares quarterly dividend
• Positive Sentiment: Coverage around CVS highlighted the company as a likely beneficiary of managed-care consolidation, with commentary that Aetna is handling medical costs and that CVS is well positioned as Walgreens weakens. Cramer’s Stop Trading: CVS Health
• Neutral Sentiment: A CVS executive, Ali Keshavarz, was appointed to the board of Choice Hotels; this is notable for the executive’s profile but does not appear to have a direct operational impact on CVS. Choice Hotels (CHH) Appoints CVS Data Chief To Board As Index Changes Hit
• Negative Sentiment: CVS and Omnicare agreed to a $440 million settlement with the U.S. Department of Justice to resolve improper billing allegations, which creates a large one-time legal cost and keeps regulatory pressure on the company. CVS, Omnicare ink $440M deal with DoJ to resolve improper billing case
• Negative Sentiment: CVS also settled a separate $36.5 million case tied to false Medicaid insulin claims, adding to the legal overhang and reinforcing concerns about compliance risks. CVS settles for $36.5M over false Medicaid insulin claims, Minnesota recovers $400K

Insider Buying and Selling at CVS Health

In other news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. This represents a 87.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the transaction, the director owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last quarter. Insiders own 0.85% of the company’s stock.

CVS Health Trading Up 1.3%

Shares of CVS traded up $1.34 on Friday, hitting $104.15. 9,355,762 shares of the stock traded hands, compared to its average volume of 7,101,005. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $106.15. The stock’s 50 day moving average is $96.91 and its two-hundred day moving average is $84.17. The firm has a market capitalization of $132.88 billion, a P/E ratio of 45.88, a P/E/G ratio of 1.02 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 23rd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 2.6%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio is presently 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.